Fertility study finds hormone that could support early pregnancy

Scientists have identified a hormone that could help prepare the womb lining for pregnancy, research shows. The hormone helps prime cells for implantation, a vital stage in early pregnancy when a fertilised egg attaches to the womb lining, the study suggests. The discovery - made by testing tissue from women aged in their forties - could help scientists develop ways to improve fertility.

Each month, as part of the menstrual cycle, hormones send chemical signals to cells in the womb lining to create conditions to support pregnancy. Fertilised eggs are extremely sensitive to changes in the womb lining, but the exact environment needed for healthy implantation is unknown.

Researchers at the University of Edinburgh tested the effects of a hormone known as DHEA on healthy tissue donated by women undergoing unrelated surgery.

They found that treating womb lining cells with DHEA in a dish doubled the level of key proteins associated with healthy implantation in the tissue.

DHEA treatment also increased the production of active androgens - hormones found in high levels in men - suggesting that these could underlie the improvement.

The study also suggests that levels of DHEA - which are known to decline significantly with age - could play a role in infertility in later life, researchers say.

They caution that it is too early to say if treatments could help women with fertility issues.

The study, published in the journal Fertility and Sterility, was funded by the Medical Research Council (MRC).

Lead author Dr Douglas Gibson, from the MRC Centre for Inflammation Research at the University of Edinburgh, said: "A fertilised egg will implant only if the conditions are just right and we were excited to see that DHEA and androgens might help improve this environment in cells. The findings will help us develop studies for potential therapies but more research is needed before we can tell if this approach could be used to help women who are struggling to conceive."

Dr Stephen Meader, Programme Manager for Reproductive Health at the MRC, said: "This study is important in learning more about what’s required for a successful implantation and healthy pregnancy. This research may be in its early stages, but it’s worthwhile because it lays the groundwork to uncovering potential treatments down the road to help women trying to conceive."

Gibson DA, Simitsidellis I, Kelepouri O, Critchley HOD, Saunders PTK.
Dehydroepiandrosterone enhances decidualization in women of advanced reproductive age.
Fertil Steril. 2018 Feb 1. doi: 10.1016/j.fertnstert.2017.12.024.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...